MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwired - May 8, 2013) - MorphoSys AG / MorphoSys to Present at Four Investor Conferences in May . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present at four upcoming international investor conferences:
Credit Suisse Antibody Day Date: May 10, 2013, 09:00am EDT (03:00pm CEST, 02:00pm BST) Venue: New York, USA Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations Deutsche Bank German, Swiss & Austrian Conference 2013 Date: May 14, 2013 Venue: Frankfurt, Germany Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG Helvea's EU Healthcare Tour Date: May 14, 2013 Venue: Frankfurt, Germany Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG BioEquity Europe 2013 Date: May 22, 2013, 05:00pm CEST (11:00am EDT, 04:00pm BST) Venue: Stockholm, Sweden Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG, Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations
The PDF version of the presentation will be provided at
www.morphosys.com . The
link to the webcast will be filed under www.morphosys.com/conference-calls .
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com .
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Conference Announcement (PDF): http://hugin.info/130295/R/1700388/561265.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1700388]
For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Loser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122 Mario Brkulj Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 Alexandra Goller Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-332 Email Contact
